患...

The study's primary end point was the incidence of hip fracture. At the end of the trial, hip fractures had occurred in 9 patients in the placebo group vs 3 in the risedronate group.The authors report that there was no difference in the fall rate between the 2 groups, suggesting "risedronate may prevent hip fractures despite frequent falls."

该试验的主要终点为髋骨骨折发生率，在试验结束时，安慰剂组有9位病患发生髋骨骨折，而服用risedronate病患则有3位发生；作者表示，这两组病患之间发生跌倒的风险并无统计上显著差异，暗示risedronate可能预防髋骨骨折，但对於跌倒风险没有影响。

Of the 54 cases,there were 46 cases of affected ureteral disappearance in IVU,8 cases of affected ureteral varicosis in pyelography,3 cases of hyperplasia of prostate in B ultrasonography,4 cases of affected renal function descended in RNI.

其中有46例在静脉尿路造影检查中患侧输尿管不显影或显示不清，8例在逆行肾盂造影中有患侧输尿管迂曲，3例在B超检查中有前列腺增生症，4例在放射性核素显像检查中有患侧肾功能下降。

Most patients receiving long-term acid suppression therapy for physician-diagnosed PUD in community practice settings are likely to have HP-negative, uninvestigated dyspepsia.

Allison医师及其同事表示，在检验及治疗曾罹患PUD病患的建议指导方针中，假设PUD可以被处理，并且成功的消灭HP可以排除未来治疗及用药的需求，大多数在社区医院经医师诊断为PUD，且接受长期酸抑制治疗的病患，常呈现HP阴性反应，且有未诊断出的消化不良症。

Results There was no significant difference in complication rate in three groups.The time when shoulder joint circumduction and ear touching recover completely both has a positive correlation with the time when shoulder joint motion starts.

结果 术后7天、14天患肢并发症的发生率前两组高于第3组，但差异无统计学意义；术后1个月、2个月、3个月及6个月患肢并发症的发生率三组差异无统计学意义；患肢肩关节环转运动、摸耳运动恢复时间分别与患者术后肩关节活动时间呈正相关。

Imatinib, a BCR-ABL tyrosine kinase inhibitor, is able to induce a complete cytogenetic response in more than 85% of patients with CML. However, the researchers note that patients with a complete cytogenic response tend to relapse when imatinib is discontinued, and less than 10% of patients achieve a molecular remission, defined by an undetectable residual disease using real-time quantitative–polymerase chain reaction.

Imatinib是一种BCR-ABL酪胺酸激酶抑制物，可以在85%以上的CML病患诱导完整的细胞生成反应；不过，研究者指出，完整细胞生成反应的病患倾向在停用imatinib时复发，不到10%的病患达到分子生物学上的缓解，其定义为以即时定量聚合酶连锁反应侦测不出残余疾病。

Imatinib, a BCR-ABL tyrosine kinase inhibitor, is able to induce a complete cytogenetic response in more than 85% of patients with CML. However, the researchers note that patients with a complete cytogenic response tend to relapse when imatinib is discontinued, and less than 10% of patients achieve a molecular remission, defined by an undetectable residual disease using real-time quantitative–polymerase chain reaction.

Imatinib是一种BCR-ABL酪胺酸激酶抑制物，可以在85%以上的CML病患诱导完整的细胞生成反应；不过，研究者指出，完整细胞生成反应的病患倾向在停用imatinib时復发，不到10%的病患达到分子生物学上的缓解，其定义为以即时定量聚合酶连锁反应侦测不出残餘疾病。

Grouping lesional and homeochronous normal hip to pair, dynamic measuring AI and AI in each age groups of lesional and normal hip on before reduction、after reduction 3rd month、6th month、9th month、12th month, describing the characteristics of acetabular development in each age groups on every observation time-points, comparing the difference of lesional acetabular development with normal acetabular physiological development.

并以患侧髋关节与同期健侧髋关节进行配对分组，动态测量各年龄组患儿患、健侧髋关节在复位前、复位后第3、6、9和12个月时的髋臼指数和髋臼深度与宽度比值AI(D/W，描述各年龄组在各时间观察点上髋臼发育的特点，比较患侧髋臼发育与健侧髋臼生理发育的差异。

The support of TPN at least for 7 days in gastric cancer patients with significant weight loss and severe malnutrition going to receiving operation maintained the nutritional status and prevented continuous weight loss. The early enteral feeding through jejunostomy tended to increase serum hemoglobin, hematocrit, and iron levels to prevent deterioration from anemia. Additionally, nutritional support gradually improved the immune function of gastric cancer patients by increasing total lymphocyte counts.

对於准备要接受胃癌手术体重明显减轻的严重营养不良病患，给予七天以上的全静脉营养支持，可维持病患之营养状况且避免体重持续减轻；术后透过空肠造口给予早期肠道营养支持，对於血清中的血色素与血比容和铁质有助上升趋势，避免贫血情况恶化；由总淋巴球数的增加发现营养支持可以渐渐恢复病患之免疫功能。

For Clark Haskins, MD, from New Mexico Oncology Hematology Consultants, Ltd, New Mexico Cancer Center, the data do not support the researchers' positive conclusions."The results were crummy," he told Medscape when asked what he thought of the strategy of using metronomic chemotherapy in advanced disease."The problem is that there are a lot of patients who don't want to take chemotherapy, so this strategy is trying to reach these patients," he said."Unfortunately, the data don't support that the strategy works."

新墨西哥癌症中心新墨西哥肿瘤血液肿瘤谘询家Clark Haskins医师表示，这项试验数据并不支持研究者的正面结论；当他被问到有关使用节律性化学疗法在进展性癌症病患的意见时，他向Medscape表示，这项试验结果并不显著，问题在於许多病患不想接受化学疗法，所以这项使用低剂量、持续使用的策略希望可以用在这些病患身上；但不幸的，这项试验的数据并不支持这样的做法是有效的。

For Clark Haskins, MD, from New Mexico Oncology Hematology Consultants, Ltd, New Mexico Cancer Center, the data do not support the researchers' positive conclusions."The results were crummy," he told Medscape when asked what he thought of the strategy of using metronomic chemotherapy in advanced disease."The problem is that there are a lot of patients who don't want to take chemotherapy, so this strategy is trying to reach these patients," he said."Unfortunately, the data don't support that the strategy works."

新墨西哥癌症中心新墨西哥肿瘤血液肿瘤咨询家Clark Haskins医师表示，这项试验数据并不支持研究者的正面结论；当他被问到有关使用节律性化学疗法在进展性癌症病患的意见时，他向Medscape表示，这项试验结果并不显著，问题在于许多病患不想接受化学疗法，所以这项使用低剂量、持续使用的策略希望可以用在这些病患身上；但不幸的，这项试验的数据并不支持这样的做法是有效的。

The split between the two groups can hardly be papered over.

这两个团体间的分歧难以掩饰。

This approach not only encourages a greater number of responses, but minimizes the likelihood of stale groupthink.

这种做法不仅鼓励了更多的反应，而且减少跟风的可能性。